Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MYC overexpression + IDH2 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

IDH2 mutation + Chr del(1p) + Chr del(19q) (9)

BCL2 rearrangement + MYC amplification (2)

HR positive + MYC amplification (2)

MYC amplification + ALK F1174L (2)

MYC expression + MYC rearrangement (2)

MYC overexpression + IDH1 mutation (2)

MYC rearrangement + LDH elevation (2)

IDH2 mutation + BRAF V600E (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion (2)

IDH2 mutation + NTRK1 fusion (2)

IDH2 mutation + NTRK2 fusion (2)

IDH2 mutation + NTRK3 fusion (2)

ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)

ALK positive + MYC amplification + CCND1 deletion (1)

EGFR T790M + MYC amplification (1)

HER-2 positive + MYC amplification (1)

HR positive + MYC mutation (1)

IDH1 mutation + MYC amplification + MAPRE1 overexpression (1)

IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)

KIF5B-RET fusion + TP53 H193R + MYC amplification (1)

MYC amplification + BCL2 amplification + TNFRSF8 expression (1)

MYC mutation + ER positive (1)

miR-17-HG deletion + MYC positive (1)

BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion (1)

IDH wild-type + FGFR3 S249C + TP53 V73fs (1)

IDH2 mutation + ALK fusion (1)

IDH2 mutation + MGMT promoter methylation (1)

IDH2 mutation + TMB-L (1)

PIK3CA mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)

PIK3CA mutation + TTN mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)

IDH2 mutation + Chr del(1p) + Chr del(19q) + MGMT promoter methylation (0)

IDH2 mutation + Chr del(1p) + Chr del(19q) (9)

BCL2 rearrangement + MYC amplification (2)

HR positive + MYC amplification (2)

MYC amplification + ALK F1174L (2)

MYC expression + MYC rearrangement (2)

MYC overexpression + IDH1 mutation (2)

MYC rearrangement + LDH elevation (2)

IDH2 mutation + BRAF V600E (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion (2)

IDH2 mutation + NTRK1 fusion (2)

IDH2 mutation + NTRK2 fusion (2)

IDH2 mutation + NTRK3 fusion (2)

ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)

ALK positive + MYC amplification + CCND1 deletion (1)

EGFR T790M + MYC amplification (1)

HER-2 positive + MYC amplification (1)

HR positive + MYC mutation (1)

IDH1 mutation + MYC amplification + MAPRE1 overexpression (1)

IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)

KIF5B-RET fusion + TP53 H193R + MYC amplification (1)

MYC amplification + BCL2 amplification + TNFRSF8 expression (1)

MYC mutation + ER positive (1)

miR-17-HG deletion + MYC positive (1)

BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion (1)

IDH wild-type + FGFR3 S249C + TP53 V73fs (1)

IDH2 mutation + ALK fusion (1)

IDH2 mutation + MGMT promoter methylation (1)

IDH2 mutation + TMB-L (1)

PIK3CA mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)

PIK3CA mutation + TTN mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)

IDH2 mutation + Chr del(1p) + Chr del(19q) + MGMT promoter methylation (0)

›

MYC overexpression + IDH2 mutation	Acute Myelogenous Leukemia	MYC overexpression + IDH2 mutation	Acute Myelogenous Leukemia	enasidenib Resistant: C3 – Early Trials enasidenib Resistant : C3	enasidenib Resistant: C3 – Early Trials enasidenib Resistant : C3
MYC overexpression + IDH2 mutation	Acute Myelogenous Leukemia	MYC overexpression + IDH2 mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3